http://rdf.ncbi.nlm.nih.gov/pubchem/patent/UA-61916-C2
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_ebb6a553affdc364c91cffe3baf12564 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P13-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-216 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P13-00 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-66 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-48 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P13-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-216 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-215 |
| filingDate | 1997-06-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2003-12-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | UA-61916-C2 |
| titleOfInvention | Method for treating urinary incontinence with (s)-oxybutynin and (s)-desethyloxybutynin and pharmaceutical composition (variants) |
| abstract | A method for treating urinary incontinence while avoiding concomitant liability of adverse effects associated with racemic oxybutynin is disclosed. The method comprises administering from 100 mg to 1000 mg/day of (S)-oxybutynin, (S)-desethyloxybutynin or a pharmaceutically acceptable salt thereof, substantially free of the corresponding R enantiomer. Pharmaceutical compositions in the form of tablets, soft elastic gelatin capsules and transdermaldevices comprising an acceptable carrier and up to 500 mg of (S)-oxybutynin or (S)-desethyloxybutynin are also disclosed. |
| priorityDate | 1996-06-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 20.